Jonathan Colasanti1,2, Marlene C Lira3, Debbie M Cheng4, Jane M Liebschutz5, Judith I Tsui6, Leah S Forman7, Meg Sullivan8, Alexander Y Walley3, Carly Bridden3, Christin Root2, Melissa Podolsky3, Catherine Abrams2, Kishna Outlaw2, Catherine E Harris2, Wendy S Armstrong1, Jeffrey H Samet3, Carlos Del Rio1,2. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 2. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Massachusetts. 4. Department of Biostatistics, Boston University School of Public Health, Massachusetts. 5. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania. 6. Section of General Internal Medicine, Department of Medicine, University of Washington and Harborview Medical Center, Seattle. 7. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Massachusetts. 8. Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Massachusetts.
Abstract
Background: Chronic opioid therapy (COT) is common in people living with human immunodeficiency virus (PLHIV), but is not well studied. We assessed opioid risk behaviors, perceptions of risk, opioid monitoring, and associated Current Opioid Misuse Measure (COMM) scores of PLHIV on COT. Methods: COT was defined as ≥3 opioid prescriptions ≥21 days apart in the past 6 months. Demographics, substance use, COMM score, and perceptions of and satisfaction with COT monitoring were assessed among PLHIV on COT from 2 HIV clinics. Results: Among participants (N = 165) on COT, 66% were male and 72% were black, with a median age of 55 (standard deviation, 8) years. Alcohol and drug use disorders were present in 17% and 19%, respectively. In 43%, the COMM score, a measure of potential opioid misuse, was high. Thirty percent had an opioid treatment agreement, 66% a urine drug test (UDT), and 12% a pill count. Ninety percent acknowledged opioids' addictive potential. Median (interquartile range) satisfaction levels (1-10 [10 = highest]) were 10 (7-10) for opioid treatment agreements, 9.5 (6-10) for pill counts, and 10 (8-10) for UDT. No association was found between higher COMM score and receipt of or satisfaction with COT monitoring. Conclusions: Among PLHIV on COT, opioid misuse and awareness of the addictive potential of COT are common, yet COT monitoring practices were not guideline concordant. Patients who received monitoring practices reported high satisfaction. Patient attitudes suggest high acceptance of guideline concordant care for PLHIV on COT when it occurs.
Background: Chronic opioid therapy (COT) is common in people living with human immunodeficiency virus (PLHIV), but is not well studied. We assessed opioid risk behaviors, perceptions of risk, opioid monitoring, and associated Current Opioid Misuse Measure (COMM) scores of PLHIV on COT. Methods: COT was defined as ≥3 opioid prescriptions ≥21 days apart in the past 6 months. Demographics, substance use, COMM score, and perceptions of and satisfaction with COT monitoring were assessed among PLHIV on COT from 2 HIV clinics. Results: Among participants (N = 165) on COT, 66% were male and 72% were black, with a median age of 55 (standard deviation, 8) years. Alcohol and drug use disorders were present in 17% and 19%, respectively. In 43%, the COMM score, a measure of potential opioid misuse, was high. Thirty percent had an opioid treatment agreement, 66% a urine drug test (UDT), and 12% a pill count. Ninety percent acknowledged opioids' addictive potential. Median (interquartile range) satisfaction levels (1-10 [10 = highest]) were 10 (7-10) for opioid treatment agreements, 9.5 (6-10) for pill counts, and 10 (8-10) for UDT. No association was found between higher COMM score and receipt of or satisfaction with COT monitoring. Conclusions: Among PLHIV on COT, opioid misuse and awareness of the addictive potential of COT are common, yet COT monitoring practices were not guideline concordant. Patients who received monitoring practices reported high satisfaction. Patient attitudes suggest high acceptance of guideline concordant care for PLHIV on COT when it occurs.
Authors: Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander Journal: Med Care Date: 2013-10 Impact factor: 2.983
Authors: Jane M Liebschutz; Ziming Xuan; Christopher W Shanahan; Marc LaRochelle; Julia Keosaian; Donna Beers; George Guara; Kristen O'Connor; Daniel P Alford; Victoria Parker; Roger D Weiss; Jeffrey H Samet; Julie Crosson; Phoebe A Cushman; Karen E Lasser Journal: JAMA Intern Med Date: 2017-09-01 Impact factor: 21.873
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: R Douglas Bruce; Jessica Merlin; Paula J Lum; Ebtesam Ahmed; Carla Alexander; Amanda H Corbett; Kathleen Foley; Kate Leonard; Glenn Jordan Treisman; Peter Selwyn Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Mark D Sullivan; Amy M Bauer; Deborah Fulton-Kehoe; Renu K Garg; Judith A Turner; Thomas Wickizer; Gary M Franklin Journal: J Pain Date: 2016-01-30 Impact factor: 5.820
Authors: Marlene C Lira; Judith I Tsui; Jane M Liebschutz; Jonathan Colasanti; Christin Root; Debbie M Cheng; Alexander Y Walley; Meg Sullivan; Christopher Shanahan; Kristen O'Connor; Catherine Abrams; Leah S Forman; Christine Chaisson; Carly Bridden; Melissa C Podolsky; Kishna Outlaw; Catherine E Harris; Wendy S Armstrong; Carlos Del Rio; Jeffrey H Samet Journal: HIV Res Clin Pract Date: 2019-04
Authors: Jessica S Merlin; Jeffrey H Samet; Debbie M Cheng; Marlene C Lira; Judith I Tsui; Leah S Forman; Jonathan Colasanti; Alexander Y Walley; Carlos Del Rio; Jane M Liebschutz Journal: J Acquir Immune Defic Syndr Date: 2019-10-01 Impact factor: 3.771
Authors: Simeon D Kimmel; Alexander Y Walley; Sara Lodi; Leah S Forman; Jane M Liebschutz; Marlene C Lira; Theresa W Kim; Carlos Del Rio; Jeffrey H Samet; Judith I Tsui Journal: AIDS Date: 2021-03-15 Impact factor: 4.632
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495
Authors: David J DiBenedetto; Kelly M Wawrzyniak; Michael E Schatman; Hannah Shapiro; Ronald J Kulich Journal: J Pain Res Date: 2019-07-23 Impact factor: 3.133
Authors: Belle Ngo; Jane M Liebschutz; Debbie M Cheng; Jonathan A Colasanti; Jessica S Merlin; Wendy S Armstrong; Leah S Forman; Marlene C Lira; Jeffrey H Samet; Carlos Del Rio; Judith I Tsui Journal: BMC Public Health Date: 2021-03-22 Impact factor: 3.295
Authors: E Jennifer Edelman; Yu Li; Declan Barry; Jennifer Brennan Braden; Stephen Crystal; Robert D Kerns; Julie R Gaither; Kirsha S Gordon; Ajay Manhapra; Jessica S Merlin; Brent A Moore; Benjamin J Oldfield; Lesley S Park; Christopher T Rentsch; Melissa Skanderson; Emily C Williams; Amy C Justice; Janet P Tate; William C Becker; Brandon D L Marshall Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771